Pharma Stocks Fall After Trump Tariff Warning – Nifty Pharma Drops 2%

Welcome Back Investor!

Indian stock markets started Tuesday on a muted note, with the Nifty 50 dipping 0.1% and the Sensex barely moving. The cautious tone comes after Donald Trump warned Tehran of “severe consequences” over reported threats to U.S. interests raising geopolitical stakes in an already fragile global environment. Add to that subdued global cues and mixed signals from Asian peers, and traders are opting for wait-and-watch mode.

Let’s dive in!

But before we start!

If you find the contents of this email useful, subscribe now & share with your friends.

Today’s Market Menu

▪️ Impact News

▪️ Markets

▪️ Everything else you need to know today

▪️ Special

▪️ Mindset

▪️ Stock Screener to up your game

IMPACT NEWS

💊 Tariff Whiplash: Trump’s Pharma Strike Sends Shockwaves Through Indian Markets

Indian pharma stocks faced a harsh dose of reality on June 17, as U.S. President Donald Trump reignited tariff fears declaring from Air Force One that pharma tariffs are “coming very soon.” The result? A sharp 2% plunge in the Nifty Pharma index, making it the worst-performing sector of the day.

Major players like Granules India and Lupin tumbled nearly 4%, while Natco, Laurus Labs, and Aurobindo Pharma followed closely behind. Even stalwarts such as Sun Pharma, Dr. Reddy’s, Cipla, and Divi’s weren’t immune, registering 1.5–2.5% losses.

This isn’t a one-off panic. It’s the third fall in four sessions, hinting at sustained volatility driven by geopolitical uncertainty and looming U.S. policy shifts. Trump’s July 9 tariff deadline feels very real now and for an export-heavy sector like Indian pharma, the implications are massive.

Interestingly, this shock came just hours after Trump departed the G7 summit early and dismissed rumors of an Israel-Iran ceasefire, teasing “something bigger.” Could pharma be the opening move in a broader trade reset?

📉 For investors, the message is clear: geopolitical signals are market signals. Indian pharma must now brace for a volatile few weeks ahead.

MARKETS

Indian markets ended in the red as selling pressure continued across the board. The Sensex dropped 213 points (-0.26%), while the Nifty 50 slipped 93 points (-0.37%) signaling a cautious mood amid global jitters. Banking and midcap indices bore the brunt, with Nifty Bank down 0.41% and Nifty Midcap 100 tumbling 0.66%, pointing to broader market weakness. With geopolitical risks and sector-specific drag weighing in, traders appear to be locking in profits and playing defensively.
_{Closing figures as on 17.06.25 (3.30pm IST)}

🔎 In Focus

Stock Performance:

Top Gainers

✅ Tech Mahindra (+1.46%) Investor optimism around upcoming AI-led service launches and digital transformation deals. The company is rumored to be in talks for a major European telecom automation project, fueling fresh buying interest.
✅ Infosys (+0.99%) Backed by reports of a potential $1.5 billion deal renewal with a US banking client. Also benefited from the broader rally in IT stocks, as the USD-INR exchange rate favored exporters.
✅ Asian Paints (+0.89%) Seasonal pre-monsoon inventory build-up and falling crude oil prices (a key input cost) improved margin sentiment. Analysts have also issued “Buy” upgrades ahead of expected rural demand pickup.
✅ TCS (+0.54%) Stability play in a volatile market, with long-term institutional buying seen. Mild gains also linked to rising expectations around Q1 earnings being resilient, especially in BFSI and cloud segments.

Top Losers

🔻 Adani Enterprises (-2.18%) Ongoing concerns about valuation and FII outflows. Recent reports suggest delays in key infrastructure projects, which triggered cautious sentiment among traders.
🔻 Sun Pharma (-2.08%) Pharma sector under pressure amid profit booking. Specifically, Sun was hit after the US FDA raised minor compliance issues in one of its Gujarat plants, creating short-term uncertainty.
🔻Dr. Reddy’s Labs (-2.08%) Part of the pharma selloff cycle. Additionally, weak sentiment followed tepid commentary on its US generics pipeline, with analysts highlighting margin compression risks.
🔻 Eternal (-1.94%) High volatility in small caps. Eternal saw sharp intraday spikes in recent sessions, and today’s decline appears to be driven by retail profit booking and lack of fresh catalysts.

INDIA FRONTIER

Everything else you need to know today

🚀 Expansion: Vedanta’s arm, Hindustan Zinc, just announced a whopping ₹12,000 crore capex plan over five years aimed at ramping up production and green tech adoption. The move signals aggressive growth despite weak metal prices.

🤝 Alliance: India is inching closer to sealing its long-awaited FTA with the European Union, with Cyprus publicly backing the deal by year-end. The pact could unlock new export channels and reduce tariff barriers across key sectors.

🚄 Momentum: India’s high-speed rail dreams just got a boost Siemens, RVNL, and GSMR have won a ₹4,100 crore contract for telecom and signalling work on the Mumbai-Ahmedabad bullet train. The project is inching closer to reality.

🔩 Resurgence: Steel Secretary Nagendra Nath Sinha announced India’s steel imports are expected to fall by 50% by FY26, aided by safeguard duties and rising domestic output. This aligns with India’s push for metal self-reliance.

SPECIAL

🔥 Bharat Coking Coal IPO: A New Spark in India’s Disinvestment Drive

Coal India’s subsidiary, Bharat Coking Coal Ltd (BCCL), is all set to debut on the stock market, and it’s already generating buzz.

As the first IPO from a Coal India unit, BCCL’s public issue is more than just another listing it’s a key milestone in India’s broader strategic disinvestment roadmap. With rising demand for coking coal, critical to the steel and infrastructure sectors, this IPO could offer investors an opportunity to tap into a vital link in India’s industrial value chain.

What makes this one worth watching?

✅ Strong parentage (Coal India Ltd)
✅ Favorable policy tailwinds in energy and infrastructure
✅ Early GMP (grey market premium) activity indicating investor interest

With the government actively streamlining PSU operations and encouraging private capital participation, this IPO is more than just a fundraising event it signals confidence in unlocking value from state-run enterprises.

That said, investors should weigh cyclicality, ESG concerns, and policy dependencies before diving in.

🚨 The question now is: Is BCCL the next power play for your portfolio or a wait-and-watch story in a transforming energy landscape?

THE HANOOMAAN INSTITUTE

💼 7 High-Income Skills That Power the Top 1% Which Are You Stacking?

The top 1% don’t just work harder they work smarter by mastering high-leverage, scalable skills that create long-term wealth and freedom.

Here are the skills they’re quietly compounding:

🔥 Sales & Persuasion: It’s not about being pushy it’s about understanding psychology and solving problems. Sales drives revenue, buy-in, and growth.

✍️ Strategic Communication & Copywriting: Clear, compelling writing influences decisions from investor decks to viral content. Copywriters who convert? Often earning $10K+ per project.

💰 Capital Allocation & Investing: Making money is step one growing it is the game. The wealthy master compounding, risk, and passive income.

🚀 Entrepreneurial Thinking They don’t just hustle they build scalable systems that earn while they sleep. This mindset creates leverage and legacy.

💻 Coding & Product Development: Digital products scale without limits. Coders who solve real problems build wealth, not just features.

🌟 Brand Building & Audience Growth: Today, attention is currency. A trusted personal brand attracts deals, clients, and capital on autopilot.

📊 Data-Driven Problem Solving: Whether streamlining ops or spotting insights, data-savvy professionals are today’s MVPs.

🧠 Final Takeaway: Top performers stack these skills layering value until opportunity comes knocking.

SUPERCHARGE YOUR INVESTING SKILLS

STOCK SCREENER TO UP YOUR GAME

Cup and handle
by Nithyanandhan

Down from 52w high AND
Market Capitalization > 1000 AND
Current price < 500 AND
Current price > DMA 50

Thanks for reading.

Until tomorrow!

Hanoomaan India Business team

Content, news, research, tools, and securities symbols are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. More details click here